Drug Profile
AEF 0117
Alternative Names: AEF-0117Latest Information Update: 18 Apr 2023
Price :
$50
*
At a glance
- Originator Aelis Farma
- Developer Aelis Farma; Columbia University; National Institute of Drug Abuse; New York State Psychiatric Institute
- Class Drug withdrawal therapies
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Substance-related disorders
Most Recent Events
- 24 Feb 2023 Aelis Farma completes a phase I trial in (indication) in Substance-related disorders (In volunteers) in USA (PO) (NCT05554926)
- 06 Jan 2023 AEF 0117 is still in phase II trials for Substance related disorders in USA (Aelis Farma pipeline, January 2023)
- 04 Jan 2023 Aelis Farma initiates enrolment in a phase I trial for substance-related disorder in the US (NCT05451017)